Wave Life Sciences retains a Hold rating as WVE-007's Phase 1 data show target engagement and visceral fat reduction but minimal weight loss. WVE-007's efficacy in obesity remains unproven versus ...
Wave Life SciencesWVE stock crashed Thursday after the company's much-hyped "body composition" drug led to just 1% weight loss over the course of six months. The company's drug, WVE-007, works by ...
Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive the stock down by more than 50% despite the biotech hailing the data as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results